Scientists test 'Living Drug' to reboot immune system in autoimmune patients
NCT ID NCT06680037
Summary
This is an early-stage study to test the safety and find the right dose of a new cell therapy called azercabtagene zapreleucel (azer-cel) for people with B-cell mediated autoimmune diseases, including progressive forms of multiple sclerosis (MS). The therapy involves modifying a patient's own immune cells (CAR T-cells) to target and reduce harmful B-cells. The main goal is to see how safe the treatment is and to determine the best dose for future, larger studies.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B-CELL MEDIATED AUTOIMMUNE DISORDERS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
TG Therapeutics Investigational Trial Site
RECRUITINGLa Jolla, California, 92093, United States
-
TG Therapeutics Investigational Trial Site
NOT_YET_RECRUITINGLexington, Kentucky, 40506, United States
-
TG Therapeutics Investigational Trial Site
RECRUITINGAnn Arbor, Michigan, 48019, United States
-
TG Therapeutics Investigational Trial Site
RECRUITINGOmaha, Nebraska, 68198, United States
-
TG Therapeutics Investigational Trial Site
RECRUITINGNew York, New York, 10025, United States
-
TG Therapeutics Investigational Trial Site
RECRUITINGRochester, New York, 14642, United States
-
TG Therapeutics Investigational Trial Site
RECRUITINGCleveland, Ohio, 44195, United States
-
TG Therapeutics Investigational Trial Site
RECRUITINGColumbus, Ohio, 43210, United States
Conditions
Explore the condition pages connected to this study.